BCL2L1 and cancer: The Bcl-2 family of proteins, especially Bcl-xL and Mcl-1, were found to be elevated in CaP and higher expression correlated with therapy resistance, thus representing a potential target for primary cancer treatment and combinatorial treatment with CRCAs [36-38, 59].